Cost-effective interventions to prevent prescription drug misuse: a systematic review

被引:0
作者
Rodriguez-Tanta, L. Yesenia [1 ]
Summers, Amanda [1 ]
Shaya, Fadia T. [1 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Practice Sci & Hlth Outcomes Res, Baltimore, MD 21201 USA
关键词
prescription drug misuse; cost-effectiveness interventions; prescription opioid misuse; cost-utility; opioids; ECONOMIC-EVALUATION; OPIOID OVERDOSE; ABUSE; BURDEN;
D O I
10.3389/fpubh.2025.1514851
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Prescription drug misuse (PDM), which involves the overprescription or inappropriate use of medications such as opioids, benzodiazepines, and stimulants, is one of the primary drivers of the opioid crisis. Identifying and understanding the most cost-effective interventions for preventing PDM is crucial. Objectives To conduct a systematic review to identify and synthesize recent cost-effectiveness studies of interventions to prevent PDM. Search methods We searched MEDLINE, EMBASE, Scopus, PsycINFO, EconLit, and Tufts CEA Registry from January 2019 until June 2024 to identify cost-effectiveness or cost-utility analyses. Selection criteria We included comprehensive economic evaluations addressing our research PICO question. Data collection and analysis Two reviewers independently screened and selected studies for inclusion, extracted study information, and assessed the quality of all included studies. The findings were synthesized narratively to provide a comprehensive overview. Main results We identified eight recent interventions of fair to good quality that focus on addressing PDM, but none of them addressed benzodiazepines or stimulants. These interventions involved modifications in prescribing behavior, distribution of naloxone in community pharmacies, the use of medication for opioid use disorder with "treatment add-ons," and education-based strategies. Variations in time horizons, comparison groups, and modeling assumptions led to differences in cost-effectiveness and quality-adjusted life years (QALYs). Nonetheless, all interventions were deemed cost-effective, particularly from a healthcare perspective. Conclusion Evidence suggests that while the identified interventions for preventing PDM are cost-effective, their scope remains limited. Further research is needed to address the misuse of other prescription drugs and to evaluate the cost-effectiveness of Prescription Drug Monitoring Programs (PDMPs), particularly their impact on clinicians' prescribing practices for patients with chronic opioid use. Additionally, incorporating societal perspectives in future studies will be crucial to enhancing policy decisions and developing comprehensive strategies to combat prescription drug misuse globally.
引用
收藏
页数:12
相关论文
共 37 条
  • [11] Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention's 2016 Opioid Guideline
    Bohnert, Amy S. B.
    Guy, Gery P., Jr.
    Losby, Jan L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 169 (06) : 367 - +
  • [12] An economic evaluation of community pharmacy dispensed naloxone in Canada
    Cid, Ashley
    Mahajan, Nikita
    Wong, William W. L.
    Beazely, Michael
    Grindrod, Kelly A.
    [J]. CANADIAN PHARMACISTS JOURNAL, 2024, 157 (02) : 84 - 94
  • [13] Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
    Claypool, Anneke L.
    DiGennaro, Catherine
    Russell, W. Alton
    Yildirim, Melike F.
    Zhang, Alan F.
    Reid, Zuri
    Stringfellow, Erin J.
    Bearnot, Benjamin
    Schackman, Bruce R.
    Humphreys, Keith
    Jalali, Mohammad S.
    [J]. JAMA HEALTH FORUM, 2023, 4 (05): : E231080
  • [14] Relationship between Nonmedical Prescription-Opioid Use and Heroin Use
    Compton, Wilson M.
    Jones, Christopher M.
    Baldwin, Grant T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (02) : 154 - 163
  • [15] Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205
  • [16] Dowell Deborah, 2022, MMWR Recomm Rep, V71, P1, DOI 10.15585/mmwr.rr7103a1
  • [17] No Shortcuts to Safer Opioid Prescribing
    Dowell, Deborah
    Haegerich, Tamara
    Chou, Roger
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2285 - 2287
  • [18] A systematic review of economic evaluations for opioid misuse, cannabis and illicit drug use prevention
    Faller, Jan
    Le, Long Khanh-Dao
    Chatterton, Mary Lou
    Perez, Joahna Kevin
    Chiotelis, Oxana
    Tran, Huong Ngoc Quynh
    Sultana, Marufa
    Hall, Natasha
    Lee, Yong Yi
    Chapman, Cath
    Newton, Nicola
    Slade, Tim
    Sunderland, Matt
    Teesson, Maree
    Mihalopoulos, Cathrine
    [J]. BJPSYCH OPEN, 2023, 9 (05):
  • [19] Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625
  • [20] Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
    Husereau, Don
    Drummond, Michael
    Augustovski, Federico
    de Bekker-Grob, Esther
    Briggs, Andrew H.
    Carswell, Chris
    Caulley, Lisa
    Chaiyakunapruk, Nathorn
    Greenberg, Dan
    Loder, Elizabeth
    Mauskopf, Josephine
    Mullins, C. Daniel
    Petrou, Stavros
    Pwu, Raoh-Fang
    Staniszewska, Sophie
    [J]. BMC MEDICINE, 2022, 20 (01)